791 related articles for article (PubMed ID: 11320369)
21. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
22. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
[TBL] [Abstract][Full Text] [Related]
23. Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure.
Mitrovic V; Mudra H; Bonzel T; Schmidt W; Strand JC; Bakovic-Alt R; Posvar EL
Clin Pharmacol Ther; 1996 Jun; 59(6):686-98. PubMed ID: 8681494
[TBL] [Abstract][Full Text] [Related]
24. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.
Gradman AH; Gray J; Maggiacomo F; Punzi H; White WB
Clin Ther; 1999 Mar; 21(3):442-53. PubMed ID: 10321414
[TBL] [Abstract][Full Text] [Related]
25. The clinical profile of the angiotensin II receptor blocker eprosartan.
Hedner T
J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
[TBL] [Abstract][Full Text] [Related]
26. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.
Roig E; Perez-Villa F; Morales M; Jiménez W; Orús J; Heras M; Sanz G
Eur Heart J; 2000 Jan; 21(1):53-7. PubMed ID: 10610744
[TBL] [Abstract][Full Text] [Related]
27. Effects of a new angiotensin-converting enzyme inhibitor, alacepril, on changes in neurohormonal factors and arterial baroreflex sensitivity in patients with congestive heart failure.
Kinugawa T; Kato M; Mori M; Endo A; Kato T; Hamada T; Noguchi N; Omodani H; Osaki S; Ogino K; Miyakoda H; Hisatome I; Shigemasa C
Eur J Clin Pharmacol; 1998 May; 54(3):209-14. PubMed ID: 9681661
[TBL] [Abstract][Full Text] [Related]
28. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.
Lee AF; MacFadyen RJ; Struthers AD
Eur J Heart Fail; 1999 Dec; 1(4):401-6. PubMed ID: 10937954
[TBL] [Abstract][Full Text] [Related]
29. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
30. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men.
Price DA; De'Oliveira JM; Fisher ND; Hollenberg NK
Hypertension; 1997 Aug; 30(2 Pt 1):240-6. PubMed ID: 9260987
[TBL] [Abstract][Full Text] [Related]
31. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Krombach RS; Clair MJ; Hendrick JW; Houck WV; Zellner JL; Kribbs SB; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
Cardiovasc Res; 1998 Jun; 38(3):631-45. PubMed ID: 9747431
[TBL] [Abstract][Full Text] [Related]
33. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
[TBL] [Abstract][Full Text] [Related]
34. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group.
Tonkon M; Awan N; Niazi I; Hanley P; Baruch L; Wolf RA; Block AJ
Int J Clin Pract; 2000; 54(1):11-4, 16-8. PubMed ID: 10750252
[TBL] [Abstract][Full Text] [Related]
35. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
Blanchet M; Sheppard R; Racine N; Ducharme A; Curnier D; Tardif JC; Sirois P; Lamoureux MC; De Champlain J; White M
Am Heart J; 2005 May; 149(5):938.e1-7. PubMed ID: 15894946
[TBL] [Abstract][Full Text] [Related]
36. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group.
Diamond JA; Gharavi A; Roychoudhury D; Machac J; Henzlova MJ; Travis A; Phillips RA
Curr Med Res Opin; 1999; 15(1):1-8. PubMed ID: 10216805
[TBL] [Abstract][Full Text] [Related]
37. Elevation of sympathetic activity by eprosartan in young male subjects.
Heusser K; Vitkovsky J; Raasch W; Schmieder RE; Schobel HP
Am J Hypertens; 2003 Aug; 16(8):658-64. PubMed ID: 12878372
[TBL] [Abstract][Full Text] [Related]
38. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK
Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802
[TBL] [Abstract][Full Text] [Related]
39. Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies.
Rayner B; Jaeger B; Verboom CN; Pascoe M
Cardiovasc J S Afr; 2004; 15(1):32-7. PubMed ID: 14997235
[TBL] [Abstract][Full Text] [Related]
40. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition.
Kiowski W; Beermann J; Rickenbacher P; Haemmerli R; Thomas M; Burkart F; Meinertz T
Circulation; 1994 Dec; 90(6):2748-56. PubMed ID: 7994817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
